Mass screening for neuroblastoma: Quo vadis? A 9-year experience from the Pediatric Oncology Study Group of the Kyushu area in Japan

Journal of Pediatric Surgery

Volumn 31, Issue 4, 1996, Pages 555-558

  Suita, S ^a   Zaizen, Y ^b   Sera, Y ^b   Takamatsu, H ^b   Mizote, H ^b   Ohgami, H ^b   Kurosaki, N ^b   Ueda, K ^b   Tasaka, H ^b   Miyazaki, S ^b   Sugimoto, T ^b   Kawakami, K ^b   Tsuneyoshi, M ^b   Yano, H ^b   Akiyama, H ^b   Ikeda, K ^b  

^a KYUSHU UNIVERSITY   (Japan)

^b NONE

Author keywords

mass screening; Neuroblastoma; prognostic factors

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER REGISTRY; CANCER SURVIVAL; CHILD; CONFERENCE PAPER; HISTOPATHOLOGY; HUMAN; INFANT; MAJOR CLINICAL STUDY; MASS SCREENING; NEUROBLASTOMA; ONCOGENE; PLOIDY; PRIORITY JOURNAL;

EID: 15844370673     PISSN: 00223468     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-3468(96)90495-9     Document Type: Conference Paper

References (17)

1. Sawada T, Sugimoto T, Tanaka T, et al: Number and cure rate of neuroblastoma cases detected by the mass screening program in Japan. Med Pediatr Oncol 15:14-17, 1987
2. Sawada T, Nagahara N, Yamamoto K, et al: Mass screening for neuroblastoma in Japan. Acta Paediatr Jpn 32:725-733, 1990
3. Sawada T: Annual report on neuroblastoma mass screening in Japan. Presented at the 10th Japanese Society of Pediatric Oncology Meeting, Kyoto, Japan, December 1994
4. Evans AE, D'Angio GJ, Randolph JA: A proposed staging for children with neuroblastoma: Children's Cancer Study Group A. Cancer 27:374-378, 1971
5. Seeger RC, Brodeur GM, Sather H, et al: Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastoma. N Engl J Med 313:1111-1116, 1985
6. Shimada H, Chattern J, Newton HW, et al: Histologic prognostic factors in neuroblastic tumours; Definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastoma. J Natl Cancer Inst 73:405-416, 1984
7. Taylor SR, Blant J, Constantino JP, et al: Flow cytometric DNA analysis of neuroblastoma and ganglioneuroma. Cancer 62:749-754, 1988
8. Tanimura M, Matsui I, Kobayashi N, et al: Evaluation of mass screening for neuroblastoma in Japan. Jpn Cancer Clinic 39:400-405, 1993
9. Bessho F, Hashizume K, Nakajo T, et al: Mass screening in Japan increased the detection of infants with neuroblastoma without a decrease in cases in older children. J Pediatr 119:237-241, 1991
10. Ishimoto K, Kiyokawa N, Fujita H, et al: Biological analysis of neuroblastoma in mass screened negative cases. Advances in Neuroblastoma Research 3. New York, NY, Wiley-Liss, pp 603-608, 1991
11. Hayashi Y, Hanada R, Yamamoto K: Biology of neuroblastomas in Japan found by screening. Am J Pediatr Hematol Oncol 14:342-347, 1992
12. Kaneko Y, Kanda N, Maseki N, et al: Current urinary mass screening for catecholamine metabolites at 6 months of age may be detecting only a small portion of high-risk neuroblastoma: A chromosome and N-myc amplification study. J Clin Oncol 8:2005-2013, 1990
13. Hachitanda Y, Ishimoto K, Hata J, et al: One hundred neuroblastomas detected through a mass screening system in Japan. Cancer 74:3223-3226, 1994
14. Nishihira K, Toyoda M, Inokuchi M, et al: Criteria of conservative treatment for mass screening positive patients without medical and surgical treatment. J J Soc Pediatr Surg 31:424, 1995 (in Japanese)
15. Hirata T, Tatara H, Zaizen Y, et al: Role of ultrasound in managing neuroblastoma detected by mass screening: A proposed ultrasonographic grading for children with neuroblastoma. J Clin Ultrasound 23:305-313, 1995
16. Woods WG, Tuchman M, Berstein ML, et al: Screening for neuroblastoma in North America: 2-year results from Quebec project. Am J Pediatr Hematol Oncol 14:312-319, 1992
17. Hayashi Y, Ohi R, Yaoita S, et al: Problems of neuroblastoma screening for 6 months old and results of second screening for 18 month olds. J Pediatr Surg 30:467-470, 1995